Market evolution: Nucleic acids (CN 293499) — 2015–2025

Introduction

This report examines the evolution of EU trade in nucleic acids, their salts, and other residual heterocyclic compounds classified under Combined Nomenclature code 293499 over the period 2015–2025. The product category is a residual heading within Chapter 29 (Organic Chemicals), encompassing a diverse range of high-value specialty chemicals used in pharmaceuticals, biotechnology, and advanced materials. The data covers EU trade with non-EU countries at annual frequency, with incomplete periods already excluded.

Over the decade under review, the EU's position in this market underwent a striking transformation. Export values more than doubled, rising from €2.83 billion in 2015 to €6.45 billion in 2025, while import values grew more moderately from €3.48 billion to €6.26 billion. The EU shifted from a trade deficit of €646 million to a surplus of €189 million. These aggregate figures, however, mask significant structural shifts in geographic concentration, price dynamics, and supply-chain vulnerabilities that merit closer examination.

For the full interactive dashboard, see the General Overview.

1. Export-Led Growth: Volume Expansion Meets Soaring Unit Values

The dominant feature of the decade is the EU's emergence as a net exporter in CN 293499, driven by a combination of rising volumes and rapidly increasing unit values. While imports grew primarily through price effects, export growth was powered by both dimensions.

1.1 The EU's trade balance turned decisively positive

The EU's trade balance with non-EU countries in this product category evolved as follows:

The balance swung from a deficit of €646 million in 2015 to a surplus of €189 million in 2025, representing a 129% improvement. Notably, the surplus peaked at approximately €4.76 billion in 2022 before narrowing sharply, suggesting that the current equilibrium is more fragile than the headline shift implies. The balance was at its minimum (−€1.34 billion) in an earlier year, and at its maximum (€4.76 billion) in 2022, indicating considerable volatility.

1.2 Export volumes grew steadily while prices accelerated

Export quantities rose by nearly a third over the decade, from 30,771 tonnes to 40,491 tonnes, with a peak of 43,260 tonnes. Import volumes grew far more modestly, at just 12.7%. The more dramatic story, however, lies in pricing: export unit values climbed 73.1% while import unit values rose 59.5%. This divergence — with exports becoming relatively more expensive than imports — is consistent with the EU moving up the value chain, exporting higher-value-added compounds while sourcing more commoditised intermediates from abroad.

1.3 Domestic production declined despite strong export performance

According to production data, EU domestic production of this product category fell from 108,000 tonnes (valued at €5.18 billion) in the first period to 86,405 tonnes (€4.24 billion) in the last — a decline of 20% in volume and 18.2% in value. This is a significant contraction. Combined with rising exports, it implies that the EU increasingly relies on imported intermediates for re-export or has shifted production toward higher-value sub-segments not captured in the aggregate tonnage figures.

The net import reliance metric, which stood at 12.4% in 2025 (having recovered from a deeply negative anomaly in earlier years), confirms that the EU is now modestly dependent on net imports relative to its production base — a notable reversal from the apparent surplus position visible in the trade balance alone.

2. Geographic Rebalancing: China's Rise and Ireland's Dominance

The geographic structure of EU trade in CN 293499 has shifted substantially, with import sources diversifying and export destinations concentrating — creating an asymmetric vulnerability profile.

2.1 China emerged as the EU's fastest-growing import source

The table below shows the evolution of the EU's top import partners by value:

China's import value surged from €336 million to €1.69 billion — a 403% increase — making it the EU's single largest import source by 2025, overtaking Switzerland. Switzerland itself grew more moderately (+25.7%) but remains a critical partner, likely reflecting the role of Swiss-based pharmaceutical and specialty chemical firms. Japan more than doubled its share (+121.4%), while India remained essentially flat. The United Kingdom, post-Brexit, grew significantly in percentage terms (+182.9%) from a low base.

2.2 The United States became overwhelmingly the primary export destination

The United States absorbed €4.63 billion of EU exports in 2025 — 72% of the total — up from €1.28 billion in 2015. This 261% growth makes the EU-US corridor the defining axis of this trade. Brazil was the fastest-growing partner in percentage terms (+374.6%), albeit from a small base. Meanwhile, exports to Japan (−28.6%) and the United Kingdom (−48.7%) declined in absolute terms, the latter likely reflecting post-Brexit trade frictions and supply-chain restructuring.

2.3 Ireland dominates EU exports; concentration has intensified dramatically

The most specialised exporters data reveals Ireland's overwhelming dominance:

Ireland's export value tripled from €1.37 billion to €4.28 billion, accounting for roughly two-thirds of total EU exports by 2025. Its revealed comparative advantage (RCA) of 12.92 and normalised RCA (RSCA) of 0.86 confirm an extreme specialisation in this product — consistent with Ireland's role as a hub for biopharmaceutical manufacturing.

This concentration is reflected in the Herfindahl-Hirschman Index for exports by value, which nearly doubled from 2,730 to 5,354 (+96.1%). An HHI above 2,500 is generally considered highly concentrated; at 5,354, EU export activity in this segment is dominated to a degree that creates structural concentration risk. In contrast, the import-side HHI declined from 2,121 to 1,848 (−12.9%), indicating moderate diversification of sourcing — driven in part by China's growing share alongside persistent Swiss and US supply.

3. Price Spikes, Pandemic Shocks, and Volatility Patterns

The decade was punctuated by notable price dislocations, particularly around the COVID-19 pandemic, that reveal the fragility of supply chains in this specialised chemical segment.

3.1 Average unit values rose dramatically across the decade

The table below traces export and import unit values (€/tonne) over the full period:

Export prices peaked sharply in 2022 at €254,002/t — nearly triple the 2017 trough — before falling back and recovering. Import prices followed a steadier upward trajectory, reaching their maximum of €188,079/t in 2025. The ratio of export-to-import prices fluctuated considerably, indicating that pricing power in this market is episodic rather than structural.

3.2 Three major price shocks were detected

The supply shock analysis identified three significant events:

The most consequential shock occurred in 2020, when EU export prices to the United States surged by 250.9%. Given that the US accounts for nearly 73% of export value, this single event had enormous market-wide impact. The simultaneous 104.2% jump in import prices from the US suggests a bilateral supply-demand disruption consistent with the early COVID-19 pandemic — when pharmaceutical and biotech demand spiked while logistics were severely disrupted.

The 2019 UK shock, while smaller in scale (84.3% price shift, 3.6% value share), had the highest abnormality score (11.6), indicating it was the most statistically unusual event — possibly linked to pre-Brexit stockpiling and supply-chain uncertainty.

3.3 Volatility differs markedly across partners

The coefficient of variation of trade values reveals which partnerships are most volatile:

Import-side volatility (selected partners):

Export-side volatility (selected partners):

On the import side, the US and China are the most stable suppliers (CV of 0.09 and 0.15 respectively), which is reassuring given their growing market share. Partners like Brazil (CV 1.63) and Singapore (CV 1.64) are highly erratic — their flows are too unpredictable to serve as reliable alternative sources. On the export side, the Republic of Korea (CV 0.14) is the most stable destination, while Canada (CV 0.84) and Russia (CV 0.58) are the most volatile — partly reflecting geopolitical and sanctions-related disruptions.

Conclusion

The EU's trade in nucleic acids and heterocyclic compounds (CN 293499) underwent a fundamental transformation between 2015 and 2025. What began the decade as a net import market evolved into a net export position, driven primarily by Ireland's pharmaceutical manufacturing boom and surging demand from the United States. Export values more than doubled, though the pace of growth relied heavily on price increases rather than proportional volume expansion.

Three structural risks stand out. First, the extreme geographic concentration of exports — with the US absorbing 72% of value and Ireland producing two-thirds of it — creates a bilateral dependency that any disruption in either country could severely impact. The 2020 pandemic price shock demonstrated this vulnerability in real time. Second, China's rapid ascent as the EU's largest import source (up 403% to €1.69 billion) raises strategic supply-chain questions, particularly in the context of broader EU-China trade policy debates. Third, the decline in domestic production (−20% in volume) even as exports grew suggests an increasing reliance on imported inputs and foreign manufacturing capacity, which may narrow the EU's trade surplus over time.

The narrowing of the trade surplus from a peak of €4.76 billion in 2022 to just €189 million in 2025, combined with import prices now consistently exceeding export prices, warrants attention. If this trend persists, the EU could return to structural deficit in this strategically important chemical segment. Policymakers and industry stakeholders should monitor these dynamics closely, particularly as global competition in specialty chemicals and biopharmaceutical intermediates intensifies.